

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vignnia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/992,800	11/06/2001	Victor Raso	BBRI-2006	7805
7:	590 09/09/2003			
Kevin M. Farrell One New Hampshire Avenue Suite 350			EXAMINER	
			PATTERSON, CHARLES L JR	
Portsmouth, NI	H 03801		ART UNIT	PAPER NUMBER
			1652 DATE MAILED: 09/09/2003	(3

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
•		09/992,800	RASO, VICTOR			
	Office Action Summary	Examiner	Art Unit			
,			1652			
.	The MAILING DATE of this communication app	Charles L. Patterson, Jr. ears on the cover sheet with the c				
Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status						
1)[\bigsi	Responsive to communication(s) filed on 2/25/02, 12/18/02, 6/13/03 and 6/30/03.					
2a)□	· · · · · · · · · · · · · · · · · · ·	s action is non-final.	-			
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4) 🖂	4)⊠ Claim(s) <u>37-106</u> is/are pending in the application.					
	4a) Of the above claim(s) 47-106 is/are withdrawn from consideration.					
5)	Claim(s) is/are allowed.					
6)⊠	Claim(s) <u>37-46</u> is/are rejected.					
7)	Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction and/or election requirement.						
·· _	ion Papers					
9) The specification is objected to by the Examiner.						
10)⊠ The drawing(s) filed on <u>06 November 2001</u> is/are: a)⊠ accepted or b)□ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action. 12) The oath or declaration is objected to by the Examiner.						
•						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:						
a)						
	 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 					
	Copies of the certified copies of the priority documents have been received in Application No Copies of the certified copies of the priority documents have been received in this National Stage					
application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.						
14)⊠ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
a) ☐ The translation of the foreign language provisional application has been received. 15)☑ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(s)						
2) Notic	te of References Cited (PTO-892) te of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal P	(PTO-413) Paper No(s) latent Application (PTO-152)			

Application/Control Number: 09/992,800

Art Unit: 1652

Applicant's election without traverse of Group I, claims 37-46 in Paper No. 12 is acknowledged.

Claims 47-106 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in Paper No. 12.

The disclosure is objected to because of the following informalities:

The first paragraph does not contain a reference to the parent application as required.

Appropriate correction is required.

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 37-46 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-8 of U.S. Patent No. 6,582,945. Although the conflicting claims are not identical, they are not patentably distinct from each other because they are apparently claiming the same antibody using different words. Page 45, line 2 through page 48, line 7 apparently shows that the vectorized antibody of the instant patent is the same as the bispecific antibody of the instant application.

Application/Control Number: 09/992,800

Art Unit: 1652

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 37-46 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

The instant specification teaches that an antibody was made using a statine analog of a transition state that would disaggregate preformed β -amyloid plaques and also had the ability to cross the blood-brain barrier. This would appear to be a hydrolytic cleavage of the β -amyloid as in claim 45. However, such an antibody has not been shown that was made using anything other that a statine analog or which has the ability to inhibit the formation of β -amyloid plaques. The process to form the plaques could well involve other processes that are not affected by the antibody. In any case the specification does not teach that the antibody will do this. Therefore, applicant have not taught one of ordinary skill in the art to make the antibody of the instant claims.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Charles L. Patterson, Jr., PhD, whose telephone number is 703-308-1834. The examiner can normally be reached on Monday - Friday, 7:30-4:00.

Application/Control Number: 09/992,800 Page 4

Art Unit: 1652

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapura Achutamurthy can be reached on 703-308-3804. The fax phone number is 703-308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Charles L. Patterson, Jr.

Primary Examiner Art Unit 1652

Patterson September 5, 2003